Selective and nonselective cyclooxygenase-2 inhibitors and experimental frature-healing: Reversibility of effects after short-term treatment

Journal of Bone and Joint Surgery

Volumn 89, Issue 1, 2007, Pages 114-125

  Gerstenfeld, L C ^a   Al Ghawas, M ^a   Alkhiary, Y M ^a   Cullinane, D M ^a   Krall, E A ^a   Fitch, J L ^a   Webb, E G ^b   Thiede, M A ^b   Einhorn, T A ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; KETOROLAC TROMETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; CALLUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FRACTURE HEALING; FRACTURE NONUNION; HISTOPATHOLOGY; LONG TERM CARE; LOW DRUG DOSE; MALE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; TREATMENT DURATION;

EID: 33846096382     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.F.00495     Document Type: Article

References (43)

1. Hodsman NB, Burns J, Blyth A, Kenny GN, McArdie CS, Rotman H. The morphine sparing effects of diclofenac sodium following abdominal surgery. Anaesthesia. 1987;42:1005-8.
2. McGlew IC, Angliss DB, Gee GJ, Rutherford A, Wood AT. A comparison of rectal indomethacin with placebo for pain relief following spinal surgery. Anaesth Intensive Care. 1991;19:40-5.
3. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-73.
4. Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol. 1984;2:335-57.
5. Vane JR, Botting RM. Mechanisms of actions of aspirin-like drugs. Semin Arthritis Rheum. 1997;26(6 Suppl 1):2-10.
6. Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford). 2005;44:846-59.
7. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acc Sci. 1999;96:272-7.
8. Roos KL, Simmons DL. Cyclooxygenase variants: the role of alternative splicing. Biochem Biophys Res Commun. 2005;338:62-9.
9. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, van de Putte LB, Abramson SB. Unresolved issues in the role of cyclooxygenase-2 in normal physiological processes and disease. Arch Internal Med. 2000;160:913-20.
10. van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Expert Opin Investig Drugs. 1997;6:609-14.
11. Chen NX, Ryder KD, Pavalko FM, Turner CH, Burr DB, Qiu J, Duncan RL. Ca(2+) regulates fluid shear-induced cytoskeletal reorganization and gene expression in osteoblasts. Am J Physiol Cell Physiol. 2000;218:C989-97.
12. Kanematsu M, Ikeda K, Yamada Y. Interaction between nitric oxide synthase and cyclooxygenase pathways in osteoblastic MC3T3-EI cells. J Bone Miner Res. 1991;12:1789-96.
13. Mack Strong VE, Mackrell PJ, Concannon EM, Mestre JR, Smyth GP, Schaefer PA, Stapleton Pp, Daly JM. NS-398 treatment after trauma modifies NF-kappaB activation and improves survival. J Surg Res. 2001;98:40-6.
14. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Eng J Med. 2001;345:433-42.
15. Sudmann E, Dregelid E, Bessesen A, Morland J. Inhibition of fracture healing by indomethacin in rats. Eur J Clin Invest. 1979;9:333-9.
16. Allen HL, Wase A, Bear WT. Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand. 1980;51:595-600.
17. Huo MH, Troiano NW, Pelker RR, Gundberg CM, Friedlaender GE. The influence of ibuprofen on fracture repair: biomechanical, biochemical, histologic, and histomorphometric parameters in rats. J Orthop Res. 1991;9:383-90.
18. Altman RD, Latta LL, Keer R, Renfree K, Hornicek FJ, Banovac K. Effect of nonsteroidal anti-inflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma. 1995;9:392-400.
19. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effects of postoperative nonsteriodal anti-inflammatory drug administration on spinal fusion. Spine. 1998;23:834-8.
20. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000;82:655-8.
21. Dumont AS, Verma S, Dumont RJ, Hurlbert RJ. Nonsteroidal anti-inflammatory drugs and bone metabolism in spinal fusion surgery: a pharmacological quandary. J Pharmacol Toxicol Methods. 2000;43:31-9.
22. Gerstenfeld LC, Thiede M, Seibert K , Mielke C, Phippard D, Svagr B, Cullinane D, Einhorn TA. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res. 2003;21:670-5.
23. Goodman SB, Ma T, Genovese M, Lane Smith R. COX-2 selective inhibitors and bone. Int J immunopathol Pharmacol. 2003;16:201-5.
24. Brown KM, Saunders MM, Kirsch T, Donahue HJ, Reid JS. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am. 2004;86:116-23.
25. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res. 2002;17:963-76.
26. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405-15.
27. Burd TA, Lowry KJ, Anglen JO. Indomethacin compared with localized irradiation for the prevention of hetrotopic ossification following surgical treatment of acetabular fractures. J Bone Joint Surg Am. 2001;83:1783-8.
28. Erratum in: J Bone Joint Surg Am. 2002;84:100.
29. Gerstenfeld LC, Einhorn TA. COX inhibitors and their effects on bone healing. Expert Opin Drug Saf. 2004;3:131-6.
30. Li M, Ke HZ, Qi H, Healy DR, Li Y, Crawford DT, Paralkar VM, Owen TA, Cameron KO, Lefker BA, Brown TA, Thompson DD. A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res. 2003;18:2033-42.
31. Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984;2:97-101.
32. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731-41.
33. Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC. The expression of cytokine activity by fracture callus. J Bone Miner Res. 1995;10:1272-81.
34. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res. 1999;14:1805-15.
35. Engesaeter LB, Sudmann B, Sudmann E. Fracture healing in rats inhibited by locally administered indomethacin. Acta Orthop Scand. 1992;63:330-3.
36. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Tsay A, Fitch J, Barnes GL, Graves DT, Einhorn TA. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res. 2003;18:1584-92.
37. Reuben SS, Ekman EF. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am. 2005;87:536-42.
38. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interieukin 6 in rat adjuvant arthritis. Arthritis J Clin Invest. 1997;97:2672-9.
39. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15.
40. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation. 2005;111:249.
41. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334-42.
42. Erratum in: Circulation. 2005;111:2412.
43. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-41.